Evofem Biosciences, Inc. (EVFM) stock
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences, Inc. grew revenue 4.5% to $18.05M over the twelve months to Jun 30, 2026. Free cash flow was -$477.00K. At the latest close the market valued the company at $865.23K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $865.23K
- P/E ratio
- –
- Price to sales
- 0.05
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -55.13%
Fundamentals
- Revenue
- $18.05M
- Net income
- -$15.28M
- EPS, diluted
- -$0.11
- Free cash flow
- -$477.00K
- Book value per share
- -$0.64
- Diluted shares
- 137M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 427,549
- Average volume (20 days)
- 147,348
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | EVFM | S&P 500 | Difference | EVFM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.9% | +0.6% | −15.5 pts | ||
| 3 months | -18.2% | +3.4% | −21.6 pts | ||
| Year to date | -33.7% | +13.3% | −47.0 pts | ||
| 1 year | -37.0% | +16.6% | −53.6 pts | ||
| 3 years | -93.0% | +86.4% | −179.4 pts | -58.8% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.9 pts | -91.4% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -76.6% | +15.4% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evofem Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Results
- Update
About Evofem Biosciences
Pharmaceutical Preparations
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing products in women's health. The company's commercial portfolio includes PHEXX (formerly known as PHEXXI), a hormone-free lactic acid, citric acid, and potassium bitartrate vaginal gel prescribed for contraception, and SOLOSEC (secnidazole) 2g oral granules. Evofem sells and markets its pharmaceutical offerings primarily through commercial distribution channels, with revenue and receivables heavily concentrated among three principal customers that constitute its primary purchasers.
Company profile, executives and historyEvofem Biosciences stock: common questions
What is Evofem Biosciences's stock price?
EVFM closed at $0.01 on Oct 19, 2026, down 10.00% on the day.
What is Evofem Biosciences's market cap?
Evofem Biosciences was worth $865.23K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is EVFM's P/E ratio?
Evofem Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.11), so it has no meaningful P/E ratio.
How much revenue does Evofem Biosciences make?
Evofem Biosciences reported revenue of $18.05M for the twelve months to Jun 30, 2026, up 4.5% from a year earlier.
Does Evofem Biosciences pay a dividend?
No. Evofem Biosciences has not paid a cash dividend over the last twelve months.
How has EVFM stock performed over the past year?
Including dividends, EVFM returned -37.0% over the past year, against +16.6% for the S&P 500.
Who are Evofem Biosciences's competitors?
Companies most similar to Evofem Biosciences by business, industry and size include EMMA, SLGL, SCYX, JAGX, DARE.
See a number that looks wrong?